Smarter cancer care

Exact Sciences brings the promise of precision medicine to life with Oncotype DX®, a full suite of genomic tests.

Learn More

NEW DATA

Landmark RxPONDER Trial Results

Publication in The New England Journal of Medicine confirms that tens of thousands of women with node-positive, early-stage breast cancer can avoid chemotherapy with the Oncotype DX® test.

LEARN MORE

GUIDELINES

NCCN Breast Cancer Guidelines

New NCCN Breast Cancer Guidelines recognize Oncotype DX Breast Recurrence Score® as the “preferred” and only multigene test to predict chemotherapy benefit in node-positive early-stage breast cancer

VIEW DETAILS

Deborah, an Oncotype DX patient

Oncotype DX® tests

Breast Cancer
New Data

The only multigene expression genomic test commercially available proven to predict a patient’s individual benefit from chemotherapy.

Learn More
Prostate Cancer

Decide whether immediate treatment is necessary or confidently opt for active surveillance. For more information, please visit our U.S. website.

Learn More
Colon Cancer

The first multi-gene expression test developed for the assessment of risk of recurrence in patients with stage II and stage III disease. For more information, please visit our U.S. website.

Learn More
Breast Cancer

The first clinically validated genomic test to quantify the risk of local recurrence (DCIS or invasive) in ductal carcinoma in situ. For more information, please visit our U.S. website.

LEARN MORE

Breast Cancer

Prostate Cancer

Colon Cancer

Improving Patient Outcomes

What Is the Test

The Oncotype DX® test reveals the underlying tumour biology to help guide treatment decisions.

Learn More

Prognostic vs. Predictive

Only a truly predictive test can identify the right treatment for the right patient.

LEARN WHY IT MATTERS

Latest TAILORx Data

The landmark TAILORx results provide definitive answers on which early stage ER+, HER2-, N0 breast cancer patients can benefit from chemotherapy.

Learn More

Contact Us

GET IN TOUCH
follow us